Valuation: Laboratorio Reig Jofre SA

Market Cap 213M 244M 197M 182M 345M 23.26B 351M 2.35B 923M 11.46B 916M 896M 39.39B P/E 2026 *
13.1x
P/E 2027 * 21.8x
Enterprise Value 298M 341M 275M 254M 482M 32.49B 490M 3.28B 1.29B 16.01B 1.28B 1.25B 55.03B EV / Sales 2026 *
0.82x
EV / Sales 2027 * 0.75x
Free-Float
20.57%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2006
Director of Finance/CFO - 20/12/2023
Chief Tech/Sci/R&D Officer - 01/01/2003
Director TitleAgeSince
Chairman - 31/12/2014
Director/Board Member 58 31/12/2014
Director/Board Member - 07/11/2017
Change 5-day change 1-year change 3-year change Capi.($)
-2.33%-2.09%+49.88%+170.51% 1,060B
-0.82%-2.30%+63.79%+62.00% 619B
-0.73%-4.98%+28.91%+82.99% 438B
+0.33%-1.17%+31.07%+27.09% 333B
-0.02%-2.85%+29.15%+45.24% 282B
-3.89%-11.22%+22.81%+27.30% 267B
+0.66%-1.42%-26.59%-37.71% 218B
-0.06%-2.88%+23.07%+62.33% 196B
-3.72%-1.10%+18.41%+70.56% 161B
Average -1.18%-3.25%+26.72%+56.70% 397.1B
Weighted average by Cap. -1.31%-2.96%+36.75%+83.91%

Financials

2026 *2027 *
Net sales 365M 417M 337M 311M 590M 39.79B 600M 4.02B 1.58B 19.6B 1.57B 1.53B 67.38B 392M 448M 361M 334M 633M 42.73B 644M 4.32B 1.7B 21.05B 1.68B 1.65B 72.37B
Net income 16.7M 19.09M 15.4M 14.23M 26.99M 1.82B 27.45M 184M 72.28M 897M 71.69M 70.13M 3.08B 9.5M 10.86M 8.76M 8.09M 15.36M 1.04B 15.61M 105M 41.11M 510M 40.78M 39.89M 1.75B
Net Debt 84.7M 96.83M 78.13M 72.16M 137M 9.24B 139M 933M 367M 4.55B 364M 356M 15.64B 78.7M 89.97M 72.59M 67.04M 127M 8.58B 129M 867M 341M 4.23B 338M 330M 14.53B
Logo Laboratorio Reig Jofre SA
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
Employees
-
Trader
-
Investor
Global
-
Quality
ESG MSCI
-